Skip to main content
SM

Save Medical Corp.

The startup has developed a medical device that employs scientifically validated digital therapy to treat lifestyle-related diseases. This technology reduces the demand on healthcare professionals and lowers overall medical costs for society.

Tokyo, Japan710+ followers
Updated 2 months ago

Funding

$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Lifestyle-related diseases place a significant burden on healthcare systems, requiring extensive resources from healthcare professionals and contributing to escalating medical costs. The demand for accessible and effective treatments for these conditions continues to grow.

Solution

Save Medical offers a digital therapeutic device designed to address lifestyle-related diseases. The device delivers scientifically validated digital therapy, providing patients with accessible and convenient treatment options. By leveraging technology, Save Medical aims to reduce the reliance on traditional healthcare settings and lower overall medical costs associated with managing these conditions. The device empowers individuals to actively participate in their health management, promoting better outcomes and improved quality of life.

Target Audience

The primary target audience includes individuals diagnosed with lifestyle-related diseases, healthcare providers seeking innovative treatment options, and healthcare organizations aiming to reduce costs and improve patient outcomes.

Features

  • Digital therapeutic intervention for lifestyle-related diseases
  • Scientifically validated treatment protocols
  • Remote monitoring capabilities for healthcare providers
  • Personalized treatment plans based on individual patient needs
  • User-friendly interface for ease of use and adherence
This profile is AI-generated and may contain inaccuracies.